Figure S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Author/s
author: James S Fraser, Shahein Tajmir, Brenton G Mar, Alison M Schram, Patrick Walters, Adam Frost, D Randal Kipp, Yakov Pechersky, David E. Shaw, Erika G Puente, Andreas Varkaris, Ramin Samadani, Michael J Holliday, Fabrizio Giordanetto, Jonathan R LaRochelle, Erika Hamilton
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.